Immuneering

IMRX Lead: Phase 3 9 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-06

Catalyst timeline

atebi + Libtayo Phase 22H 2026atebi + Libtayo Phase 2, 2H 2026, routine
Atebimetinib IMM-1-104 Ph3 start4Q 2026Atebimetinib IMM-1-104 Ph3 start, 4Q 2026, routine
Second DCI program IND filingMid-2027Second DCI program IND filing, Mid-2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

atebimetinib

IMM-1-104

Small Molecule Target: MEK, ERK, KSR, MAPK, MAPK pathway

Pancreatic Ductal Adenocarcinoma Phase 3 oral NCT05585320
Non-Small Cell Lung Cancer Phase 1 oral Eli Lilly and Company NCT05585320
Melanoma Phase 1 oral NCT05585320
Advanced Solid Tumors Phase 1 Phase 1/2a trial oral NCT05585320

envometinib

IMM-6-415

Small Molecule Target: MEK, ERK

Undisclosed indication Phase 1 oral NCT06208124

Technology platforms

Deep Cyclic Inhibition

DCI platform leveraging translational bioinformatics and 3D tumor modeling to design small molecule Deep Cyclic Inhibitors targeting core cancer signaling pathways including MAPK (RAS/RAF/MEK/ERK) and other oncogenic pathways, with focus on solid tumor oncology.

Targets: MEK, ERK, MAPK pathway

Disease Cancelling Technology

DCT is a computational target identification platform using human transcriptomic data to identify novel drug targets and new ways to modulate existing targets for oncology drug discovery; disease-agnostic but currently focused on oncology.

Biotech Distilled coverage (9)

2026-08-06 UPDATE: Immuneering (IMRX) - The Quiet Quarter, and the CFO Who Sold a Company for $6.7B 🔒 Paid
2026-06-11 UPDATE: Immuneering (IMRX) - First Patient Dosed. The 2028 Clock Starts.
2026-06-02 UPDATE: Immuneering (IMRX) - The Data Hit. The Stock Got Hit Harder. 🔒 Paid
2026-05-21 UPDATE: Immuneering (IMRX) - 17.3 Months. The Number Prints. 🔒 Paid
2026-05-16 UPDATE: Immuneering (IMRX) - The 27-Month Monotherapy Patient 🔒 Paid
2026-04-27 UPDATE: Immuneering (IMRX) - The Resistance Question Gets an Answer 🔒 Paid
2026-03-07 UPDATE: Immuneering (IMRX) - FY2025 Wrap-Up 🔒 Paid
2026-01-07 UPDATE: Immuneering (IMRX) – 14.8 Months Median Survival (So FAR). Gravity Kicks In, But the Signal Survives. 🔒 Paid
2025-12-29 Immuneering Corporation (IMRX): Scientific Due Diligence Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.